Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alamar BiosciencesALMR +13.15%12 PB Ratio is 8.04 as of Sep. 18, 2026, which is 28% above its 10-year median of 6.30. GuruFocus rates ALMR with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 785 Medical Devices & Instruments companies, Alamar Biosciences ranks worse than 86.88% on this metric.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Alamar Biosciences PB Ratio Related Terms
Alamar Biosciences PB Ratio Historical Data
* Premium members only.
The historical data trend for Alamar Biosciences's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alamar Biosciences PB Ratio Chart
Alamar Biosciences Annual Data
Trend
Dec24
Dec25
PB Ratio
0.00
0.00
Alamar Biosciences Quarterly Data
Mar25
Jun25
Mar26
Jun26
PB Ratio
0.00
0.00
0.00
6.01
ALMR vs ESTA, NVCR, BFLY: PB Ratio Comparison
For the Medical Devices subindustry, Alamar Biosciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alamar Biosciences PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Alamar Biosciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Alamar Biosciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Alamar Biosciences (ALMR) has a PB Ratio of 8.04 as of Sep. 18, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Alamar Biosciences and its competitors. This is 28% above median its historical median of 6.30. Over the past decade, Alamar Biosciences' PB Ratio has ranged from 5.62 to 8.37. According to the industry distribution chart, Alamar Biosciences ranks #682 out of 785 companies in the Medical Devices & Instruments industry, placing it in the top 86.9%.
Is Alamar Biosciences' PB Ratio too high?
Alamar Biosciences' current PB Ratio of 8.04 is 28% above median its 10-year median of 6.30. Over the past 10 years, this metric has ranged from a low of 5.62 to a high of 8.37. The Medical Devices & Instruments industry median PB Ratio is 2.14. Alamar Biosciences' value of 8.04 is 275.7% above this industry median. Based on the distribution chart, Alamar Biosciences ranks #682 out of 785 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Alamar Biosciences has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Alamar Biosciences' PB Ratio compare to ESTA and NVCR?
According to the Medical Devices & Instruments industry distribution chart, Alamar Biosciences ranks #682 out of 785 companies for PB Ratio. This places Alamar Biosciences in the lower half of its industry. The industry median PB Ratio is 2.14. Alamar Biosciences' value of 8.04 is 275.7% above this benchmark. Historically, Alamar Biosciences' own PB Ratio has ranged from 5.62 to 8.37 over the past decade. While the company's 10-year median is 6.30 vs. the industry median of 2.14, Alamar Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.14, based on 785 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alamar Biosciences's current PB Ratio of 8.04 is 275.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Alamar Biosciences and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alamar Biosciences's current PB Ratio is 8.04, which is 28% above median its own 10-year median of 6.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alamar Biosciences stock overvalued right now?
Alamar Biosciences (ALMR) has a current PB Ratio of 8.04. The current PB Ratio is 8.04, which is 28% above median its 10-year median of 6.30 and 275.7% above the Medical Devices & Instruments industry median of 2.14. Alamar Biosciences' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Alamar Biosciences (ALMR), the current PB Ratio is 8.04 as of Sep. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.
12GF Score
Get the complete analysis for ALMR
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALMR has been successfully added to your 
